Deep Immune Profiling of Anti-tumor Immunity

A myriad of different lymphocyte types infiltrate tumors at different time points of tumor development, and not all are equally beneficial to the overall anti-tumor immune response. In similar fashion, not all tumor-infiltrating lymphocytes (TIL) respond equally well to biologic-based immunotherapies or serve equally well as platforms for adoptive transfer modalities. My laboratory is interested in deep immune profiling during the anti-tumor immune response to identify specific populations or lymphocyte clones that represent the best responders to immunotherapy or contain the best antigen receptors (TCR/BCR) from which to make novel gene-modified cell therapies. To this end, we utilize high parameter flow cytometry and cell sorting.